Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients

NCT00189774 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00189774
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00189774 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients
Lead sponsor
Astellas Pharma Inc
Phase
Phase 2/3
Overall status
Completed
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, type ii, type 2 diabetes mellitus